Vertex Ventures HC
Venture capitalSingapore · Seed–Growth · 4 people tracked
Find your way into Vertex Ventures HC
1,555 people in our graph share verified history with the Vertex Ventures HC team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Vertex Ventures HC invests in life science innovation, backing healthcare companies that develop transformative therapies and medical technologies. As part of Vertex's global venture network spanning China, Israel, Japan, Southeast Asia, India and the US, the fund concentrates on building a portfolio positioned to advance through key clinical, growth and value-creation milestones. Its track record includes FDA-cleared products and multiple clinical-stage assets across its portfolio companies.
Source: firm website, verified Aug 7, 2026.
Team · 4 people
from public directories
What they invest in
from 9 of 10 portfolio companiesBiotech ×8Healthtech ×5Medical Devices ×2AI & Machine Learning ×1Deep Tech ×1
HQs:United States×7
Investments · 10 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 22023 · 12021 · 12020 · 12019 · 17 dated
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)inKEVIN LEE(Executive Officer, Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalLongwood FundSR One Capital ManagementSV Health Investors+2 more
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.
BiotechHealthtechHouston, US
Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)
Co-investorsLeaps by BayerRA Capital
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.
BiotechMedical DevicesSan Diego, US
Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Pam Taub, M.D., FACC(Co-founder)
Co-investorsBluebird VenturesBroadview VenturesLongitude CapitalAdams Street PartnersARCH Venture PartnersVertex Ventures
HealthtechFremont, US
Anton Clifford(Executive Officer)inJames Leech(Executive Officer)inChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)
BoardJoshua Makower(Director)Shahzad Malik(Director)in
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Gilde Healthcare
Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder.
BiotechHealthtechMedical DevicesSan Jose, US
Alexander Yeh(Founder)inMilton M. Morris(Executive Officer, Director)inDave Van Meter(Chief Executive Officer)Steve Paul(Chief Commercial Officer)in
Co-investorsCerity Partners VenturesForeground CapitalPortfoliaTreo Ventures, LlcWindham Capital PartnersAction Potential Venture Capital Ltd.
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.
BiotechHealthtech
Peter Barrett(Co-founder & Board Member)inTom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)inParameswaran Hari(Chief Medical Officer)inJulie Feder(Chief Financial Officer)inDana Alexander(Chief Technical Officer)in
Co-investorsAtlas VentureTCG Crossover
BiotechWaltham, US
James W. Broderick(Executive Officer, Director)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)
BoardJens Eckstein(Director)
Co-investorsSR One Capital ManagementBioHealth Innovation, Inc.Pfizer VenturesTakeda Ventures
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalThird Rock Ventures
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibodies for cancer, including lead candidate TORL-1-23 targeting CLDN6 in ovarian cancer.
BiotechCulver City, US
Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)
Co-investorsOCV PartnersRA CapitalCowen Healthcare InvestmentsGoldman SachsPerceptive Xontogeny Venture
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BlackThorn Therapeutics
Exits · 1
1 IPOsBicycleNASDAQ: BCYC
Portfolio news
latest coverage across their companiesTorl Bio · endpoints.news · Oct 7, 2025
Epirium · endpoints.news · Jul 25, 2025
Palleon Pharmaceuticals · nasdaqprivatemarket.com · Jun 27, 2025
Frequently asked questions
- How many investments has Vertex Ventures HC made?
- Vertex Ventures HC has 10 tracked investments, 1 of which have exited, including 1 dated in the last 24 months.
- What stage does Vertex Ventures HC invest at?
- Vertex Ventures HC invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Vertex Ventures HC's typical check size?
- Vertex Ventures HC typically writes checks of $500K – $10M.
- What sectors does Vertex Ventures HC focus on?
- Vertex Ventures HC focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Vertex Ventures HC located?
- Vertex Ventures HC is headquartered in Singapore, SG.
- Who does Vertex Ventures HC co-invest with?
- Vertex Ventures HC most often shares deals with Atlas Venture, Longwood Fund, RA Capital, among 11 tracked co-investors.
Media · Podcasts & interviews
featuring the teamBiotech Trends & Innovations with Christine Brennan and Lori Hu, Vertex Ventures HC
Vertex · Lori Hu
Images
Co-investors · 10
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
HOF Capital is a New York-based venture capital firm investing in companies transforming foundational industries through advanced software and AI.
The National Science Foundation (NSF) is a U.S. federal government agency that funds research and education across science and engineering fields, supporting researchers, students, educators and organizations nationwide through grants.
Illuminate Ventures is an early-stage venture firm focused on B2B/enterprise software startups, typically serving as a company's first institutional investor.
Foothill Ventures is a technology-focused venture fund based in Los Altos, California, run by a team with founder and operator backgrounds. It makes early-stage investments in frontier technology, particularly infrastructure and AI applications.
Johnson & Johnson Innovation is the innovation arm of Johnson & Johnson, working to advance life science innovation through early partnerships, incubation via JLABS, venture investing through JJDC, and late-stage partnerships to address global health challenges.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Firms observed investing alongside Vertex Ventures HC, from public investor directories. Shared companies are the overlap with Vertex Ventures HC's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.